TrialThe Lancet. Haematology2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
126 papers cite itlatest 60 shown
this paperpooled ittrialcites it